Sotorasib, a selective KRAS inhibitor that specifically targets KRASG12C has been approved by the U.S. Food and Drug Administration for locally advanced or metastatic non-small-cell lung cancer harboring KRASG12C mutation.9,10 However, the major resistance mechanism for KRASG12C inhibitors was through RAS-ERK reactivation or a novel KRAS switch-II pocket mutation has emerged.11,12 The other strategy has been proposed to target Ras effectors, including MEK. This evidence concerns the gene KRAS and non-small cell lung carcinoma.